Drugs that contain Naldemedine Tosylate
1. Drug name - SYMPROIC
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(4 years from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(5 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(9 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(10 years from now) | |
| CN101228172A | BDSI | 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| CN101228172B | BDSI | 6, 7-Unsaturated -7-Carbamoyl Substituted Morphinan Derivative. |
May, 2026
(3 years from now) | |
| CN103298819B | BDSI | 6, 7-Unsaturated -7 - Carbamoyl Morphinan Derivative Crystal And Preparation Method Thereof |
Nov, 2031
(9 years from now) | |
| CN105131003A | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| CN105131003B | BDSI | 6, 7-Unsaturated -7 - Carbamoyl-Morphinan Derivative Crystal And Its Preparation Method |
Nov, 2031
(9 years from now) | |
| CN103298819A | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| IN200705325P4 | BDSI | 6, 7-Unsaturated-7-Carbamoyl-Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| IN264360B | BDSI | 6,7-Unsaturated-7-Carbamoyl-Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| IN315783B | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| EP1889848A1 | BDSI | 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| EP1889848B1 | BDSI | 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| EP1889848A4 | BDSI | 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| EP1889848B8 | BDSI | 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative |
May, 2026
(3 years from now) | |
| EP3560929A2 | BDSI | Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate |
Nov, 2031
(9 years from now) | |
| EP3560929A3 | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| EP2639234B1 | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| EP2639234A1 | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| EP2639234A4 | BDSI | Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same |
Nov, 2031
(9 years from now) | |
| EP3560929B1 | BDSI | Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate |
Nov, 2031
(9 years from now) | |
| EP2851075B1 | BDSI | Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative |
May, 2033
(10 years from now) | |
| EP2851075A1 | BDSI | Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative |
May, 2033
(10 years from now) | |
| EP2851075A4 | BDSI | Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative |
May, 2033
(10 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.2MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.